Background Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis. Functional vitamin K deficiency may further contribute to their susceptibility for VC. We investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation.
thromboembolic risk in this patient population. 1, 2 In addition, a disproportionately increased hazard of bleeding, in particular of hemorrhagic stroke, may tilt the benefit-to-risk ratio of VKAs toward a net harm. 1, 2 Finally, ample circumstantial evidence implicates VKAs in the development of vascular calcifications (VCs), although high-quality clinical data are currently lacking. 3, 4 VKAs exert their anticoagulant effects by blocking the ɤ-carboxylation of coagulation factors. Inevitably, they also prevent the activation of other vitamin K-dependent proteins, some of which play a germane role in the inhibition of VC, including matrix Gla protein (MGP), Gla-rich proteins, and growth arrest-specific protein 6. The procalcific effects of VKAs are thus intrinsic to their mode of action. Notwithstanding the controversy, current guidelines recommend the consideration of VKAs in patients with a CHA 2 DS 2 -VASc score $2 5, 6 and VKAs are still commonly used in the dialysis population with AF, albeit with a large practice variability and physician uncertainty. 7 In the past few years, the use of direct oral anticoagulants (DOACs) in the hemodialysis population as an alternative for VKAs has gathered momentum, despite a paucity of data on their safety and effectiveness and specific dosing guidelines. DOACs may have a better risk-benefit profile, because they provide more on-target anticoagulation and are associated with lower rates of intracerebral bleeding. Furthermore, they are not expected to accelerate the progression of VC, because they do not interfere with vitamin K metabolism. Selective inhibition of factor Xa may even have beneficial effects on the development of atherosclerosis. [8] [9] [10] Patients with CKD, and in particular those on dialysis, have a high prevalence of subclinical vitamin K deficiency. 11 Because the propensity for VC may be a key corollary of vitamin K deficiency, vitamin K supplements have garnered attention as a means to improve the dismal cardiovascular prognosis in the dialysis population. However, whether correction of vascular vitamin K status has a beneficial effect on the progression of VC in patients on dialysis is currently unknown. 11 This study was designed to examine the effect of vitamin K deficiency on the development of VC in the hemodialysis population. Patients on hemodialysis treated with VKAs epitomize a status of severe vitamin K deficiency, which we sought to compare with replete vitamin K stores as attained by withdrawal or avoidance of VKA plus administration of highdose vitamin K supplements. To delineate the contribution of each measure, an intermediate group was included in whom anticoagulation was achieved by a DOAC without additional vitamin K supplements.
Computed tomography scan of the heart and thoracic aorta is a reliable technique to assess the extent of VC in patients on hemodialysis. 12 High calcification scores identify patients at risk for cardiovascular events and death. 13, 14 Calcification scores have been widely used as surrogate markers to assess the effect of an intervention on cardiovascular risk in patients with CKD and on hemodialysis. [15] [16] [17] Arterial stiffness quantified by pulse wave velocity (PWV) correlates with calcification scores and also predicts cardiovascular disease and mortality. 18, 19 We therefore used these methods to evaluate VC extent and progression in our study. Dephosphorylated uncarboxylated MGP (dp-ucMGP) is the inactive form of MGP and is currently considered to be the most accurate biomarker for vascular vitamin K stores when vascular end points are studied. 11 Hence, systemic dp-ucMGP levels were also measured to assess vitamin K status in each treatment group.
METHODS

Trial Design
This study is an investigator-driven, randomized, prospective, open-label interventional clinical trial, conducted at three sites in Belgium (AZ Sint-Jan Brugge, Onze Lieve Vrouw Ziekenhuis Aalst, ZNA Middelheim Antwerpen). The study was approved by appropriately authorized ethics committees in all participating sites and registered on Clin-icalTrials.gov (identifier NCT02610933). The design of the study has been described in detail previously. 4 The study has a three-arm parallel group design with a 1:1:1 allocation ratio (Supplemental Figure 1 ).
Participants
Adults on chronic hemodialysis with nonvalvular AF, with a CHA 2 DS 2 -VASc score of $2, and therefore candidates for anticoagulation therapy or already receiving VKAs, were eligible for inclusion. Inclusion and exclusion criteria are listed in the Supplemental Material. All patients provided written, informed consent.
Interventions and Measurements
Patients in the first treatment arm were started on a VKA or continued the VKA, with dose adjustments to achieve an international normalized ratio of 2-3 on the basis of weekly international normalized ratio measurements. Time in the therapeutic range was recorded. Patients in the second treatment arm received a daily dose of 10 mg rivaroxaban. The
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choice of this dose was on the basis of a comprehensive pharmacokinetic and pharmacodynamic analysis in patients on hemodialysis, revealing that a dose of 10 mg provided a similar exposure as a dose of 20 mg in healthy individuals. 20 Patients in the third treatment arm received a daily dose of 10 mg rivaroxaban and 2000 mg menaquinone-7 (MK-7) thrice weekly after dialysis with directly observed therapy to ensure adherence. MK-7 is a form of vitamin K2 that has a superior absorption and bioavailability as compared with other menaquinones and vitamin K1. 21, 22 The choice of the dose was on the basis of a short-term dose-finding study in patients receiving chronic hemodialysis. 23 Incremental doses of 360, 720, and 1080 mg MK-7 thrice weekly resulted in a doseproportional decrease of the dp-ucMGP levels (17%, 33%, and 46%, respectively), without achieving a plateau phase. 23 For this study, the dose of MK-7 was therefore increased to 2000 mg thrice weekly.
Clinical data, biochemical data, imaging data, and PWV data were collected at baseline, 6, 12, and 18 months. Subjective tolerability was evaluated by questioning the patients about adverse events or by spontaneous reporting of adverse events by the patients. Objective tolerability was evaluated by monitoring vital signs and routine clinical laboratory tests. Primary outcome measures were change of coronary artery calcification, thoracic aorta calcification, and PWV over 18 months versus baseline. Secondary outcome measures are listed in the Supplemental Material.
Biochemical Analysis
Blood samples were taken at the start of dialysis at the dialyzer inlet line. Plasma was obtained by 15 minutes of centrifugation with a Rotina 38R and stored at 280°C in three aliquots of 1 ml until dry-ice shipment for central analysis. Circulating dp-ucMGP was quantified using an automated assay (Ina K tif MGP iSYS kit; IDS, Boldon, UK).
Imaging
For calcification assessment, an unenhanced electrocardiographically gated computed tomography of the heart and thoracic aorta was performed at 120 kV on a Revolution (GE Healthcare), Aquillion One (Toshiba), or Somatom Definition Flash (Siemens) scanner. To limit artifacts owing to high heart rates (.70 Bpm), b-blockade (bisoprolol 2.5-5 mg) was administered orally 60 minutes before scanning when necessary. Calcium scores were calculated on 2.5-mm slices using Smartscore v.4.0 (GE Healthcare) by the Agatston method 24 and by the volume method. 25 All foci within the arteries with attenuation .130 Hounsfield units (Hu) and a minimum area of 1 mm 2 were considered significant and were counted into the total score. An Agatston score for each calcific lesion was calculated by multiplying the density factor (1, Hu; 2, 200-299 Hu; 3, 300-399 Hu; and 4, $400 Hu) by the area. A total Agatston score was obtained by adding the scores of all individual lesions in all slice levels. The total volume score was obtained by adding the volumes of all .130 Hu lesions. One experienced investigator (L.P.) reviewed all scans for consistency of interpretation. For each subject, all imaging procedures were done on the same equipment using the same parameters at each session to permit valid longitudinal image comparisons. Scans started in the upper thorax above the aortic arch, advancing caudally to the level of the diaphragm to include the coronary arteries, the aortic and mitral valve, and the ascending and descending thoracic aorta. Segments with stents were excluded from the analysis. In patients with coronary artery bypass grafts, the coronary arteries were excluded from the analysis in case of imaging artifacts.
PWV
Hemodynamic measurements were performed in the supine position by trained research nurses during the first hour of the midweek dialysis session. Mean arterial pressure (MAP) was calculated as diastolic BP+0.43(systolic BP-diastolic BP), on the basis of the mean of two measurements. PWV was obtained by sequential recording of electrocardiogram-gated carotid and femoral artery pressure waves using applanation tonometry (SphygmoCor version 7; AtCor Medical, Sydney, Australia), as described previously. 26 The path length was calculated as 0.8 times the direct distance between the carotid and femoral recording sites. PWV was calculated as the path length divided by transit time (m/s).
Statistical Methods
Sample size calculation, randomization method, and blinding considerations are described in the Supplemental Material. Descriptive statistics used were proportions, means, SDs, medians, and interquartile ranges (IQRs). Baseline and end-ofstudy characteristics at 18 months were compared between the study arms according to Fisher's exact test for categoric variables and the Kruskal-Wallis test for continuous variables. Associations between baseline dp-ucMGP levels and PWV, calcification scores, and dialysis and warfarin vintages were evaluated using Spearman rho coefficients, partialized for age, sex, body mass index, systolic BP, presence of diabetes, parathyroid hormone, calcium, phosphate, cardiovascular history, and statin use. Percentage changes in calcification scores were calculated as the change in calcification scores from baseline divided by the baseline value+1, the latter to account for zero values at baseline. Percentage changes at 18 months were annualized by dividing them by a factor of 1.5. Proportions of "rapid progressors," i.e., patients with an annualized percentage change of $15%, were compared between treatment groups according to Fisher's exact test. To account for clustering of multiple observations over time within patients, changes from baseline were analyzed according to mixed linear regression modeling for continuous data (dp-ucMGP levels, other laboratory parameters, calcification scores, PWV, MAP) and mixed logistic regression modeling for binary data (use of cinacalcet, sevelamer, calcium containing binders, and alfacalcidol). In these models, a random intercept at the patient level was used, time as a fixed factor, and an unstructured covariance matrix. Differences in changes over time across treatment groups were analyzed by evaluating the treatment-by-time interaction in these mixedeffects models. To deal with the considerable skewness in both calcification scores and in their changes, Agatston and volume were entered in these models after square root transformation in line with previous studies. 27 Goodnessof-fit statistics for all models demonstrated acceptable fit to the data. Estimated marginal mean changes from baseline and their 95% confidence intervals at 6, 12, and 18 months, as depicted in Figures 1, A and B and 2, A-D, were obtained from the mixed models. Survival times, as well as times to the first bleeding episode occurring during the total observation period of 18 months, were compared between the treatment arms using Cox proportional hazards models. The total number of bleeding events across patients was compared using Poisson regression analysis. We considered a two-sided P value ,0.05 to indicate statistical significance. All analyses were on the basis of the intentionto-treat principle.
RESULTS
Participants
Between February of 2015 and July of 2017, 143 patients on hemodialysis with documented AF were evaluated and 132 enrolled (Supplemental Figure 2 ). The overall study population was almost exclusively of western European ancestry, and had a median dialysis vintage of 2.4 years with 16.7% patients receiving incident dialysis, a median CHA 2 DS 2 -VASc score of 5.0 with a 30.3% history of stroke, a median warfarin vintage of 1.1 years including 34.8% patients with a warfarin vintage ,3 months and 25.8% patients who were warfarin-naïve, and a median HAS-BLED score of 5.0 with a 28.0% history of gastrointestinal bleeding. Baseline demographic and clinical characteristics (Table 1) , baseline biochemical characteristics (Supplemental Table 1 ), and baseline maintenance medication (Supplemental Table 2 ) were not different between the groups. Baseline calcification scores ( Table 2 ) and baseline hemodynamic parameters and PWV (Table 3) were not significantly different across the treatment arms.
The 132 patients represented 163.5 person-years of observation over the course of the study. Follow-up was incomplete in 55 patients, due to death (n=47) or withdrawal of consent (n=8). In 14 patients, the study drug (VKA or rivaroxaban) was discontinued, in all but one case (patient unwilling) as a consequence of a bleeding event. In the rivaroxaban+vitamin K2 arm, only rivaroxaban was withdrawn and vitamin K2 supplements were continued (Supplemental Figure 2) .
Median (IQR) dp-ucMGP at baseline was 1983 (1486-3087) pmol/L in the VKA arm, 1632 (1083-2390) pmol/L in the rivaroxaban arm, and 1598 (1058-3324) pmol/L in the rivarox-aban+vitamin K2 arm (P=0.12). Baseline dp-ucMGP levels were strongly correlated with warfarin vintage (partial Spearman rho, +0.44, P,0.001) after adjustment for age, sex, body mass index, systolic BP, presence of diabetes, parathyroid hormone, calcium, phosphate, cardiovascular history, and statin use. No significant associations between baseline dp-ucMGP and baseline calcification scores, baseline PWV (partial Spearman rho, 20.19, P=0.17), or dialysis vintage (partial Spearman rho, 20.09, P=0.32) were observed. Mixed modeling demonstrated that the change in dp-ucMGP levels over time was significantly different across treatment arms (P,0.001) ( Figure 1A ). Dp-ucMGP levels increased significantly in the VKA arm (P=0.03), whereas levels decreased significantly in the rivaroxaban arm (P=0.04) and the rivaroxaban+vitamin K2 arm (P=0.04). In the rivaroxaban and rivaroxaban+vitamin K2 groups, dp-ucMGP levels dropped significantly after 6 months and remained stable from then on throughout the entire observation period (P=0.65). Decreases in dp-ucMGP levels were significantly larger when vitamin K2 was added to rivaroxaban (P=0.004). At 18 months, median (IQR) dp-ucMGP was 2967 (1982-4737) pmol/L in the VKA group, 981 (729-1453) pmol/L in the rivaroxaban group, and 853 (707-1176) pmol/L in the rivaroxaban+vitamin K2 group (P,0.001). Drops in dp-ucMGP levels induced by vitamin K2 were not associated with diabetes status (P=0.48) or with the use of phosphate binders (P=0.42). In the subgroup of patients who were warfarin-naïve (n=34, 25.8%), the change in dp-ucMGP levels over time was also significantly different across treatment arms (P,0.01), with an increase in the VKA group, stable levels in the rivaroxaban group, and a decrease in the rivaroxaban+vitamin K2 group ( Figure 1B) . Over the course of the 18 months of observation, changes in calcium, phosphate, parathyroid hormone levels, and HgA1c (in patients with diabetes); in MAP; and in use of phosphate binders, cinacalcet, and active vitamin D were not significantly different between the study groups (Supplemental Table 3 ).
Primary Outcomes
Mixed model analyses revealed that longitudinal changes in calcification were not significantly different between the treatment groups (total coronary arteries Agatston score P=0.36, total coronary arteries volume score P=0.62, thoracic aorta Agatston score P=0.21, thoracic aorta volume score P=0.71; Figure 2 , A-D). The percentage changes from baseline values over 18 months in Agatston calcification scores and calcium volume scores were not significantly different between the treatment groups (Tables 4 and 5). After 18 months, the proportion of patients with an annualized percentage change in Agatston calcification scores of $15% was not different between the VKA, rivaroxaban, and rivaroxaban+vitamin K2 arms: 50.0%, 47.4%, and 40.0% (P=0.87) for the sum of the coronary arteries and 50%, 44.4%, and 50.0% (P=0.91) for the thoracic aorta, respectively. Similarly, the proportion of patients with an annualized percentage change in volume scores of $15% was not different between the VKA, rivaroxaban, and rivaroxaban+vitamin K2 arms: 50.0%, 38.9%, and 50.0% (P=0.75) for the sum of the coronary arteries and 50.0%, 38.5%, and 46.2% (P=0.76) for the thoracic aorta, respectively.
Mixed modeling revealed that the change in PWVover time was not significantly different across treatment arms (P=0.56). When MAP was included as a time-varying covariate in the model, the change in PWVover time was also not significantly different across treatment arms (P=0.12).
Secondary Efficacy Outcomes
The rates of all cause death were 36.0/100 person-years in the VKA group, 26.0/100 person-years in the rivaroxaban group, and 24.6/100 person-years in the rivaroxaban+vitamin K2 group (Supplemental Figure 3 ; P=0.47). The main causes of death were withdrawal of dialysis, infectious disease, and sudden death (Supplemental Table 4 ). An ischemic or uncertain type of stroke occurred in eight of the 132 patients, corresponding with a stroke rate of 4.89/100 personyears. A hemorrhagic stroke was diagnosed in two of the 132 patients, corresponding with a stroke rate of 1.22/100 person-years. The number of strokes did not differ between the treatment groups, although it is noticeable that both hemorrhagic strokes occurred in the VKA group (Table  6 ). Mean (SD) CHA 2 DS 2 -VASc score was 5.13 (1.13) in the patients that developed an ischemic stroke versus 4.67 (1.44) in those that did not (P=0.26). A history of stroke was recorded in 62.5% (five of eight) of patients with an ischemic stroke and in 28.2% (35 of 124) of those without a stroke during the study period (P=0.06). An exploratory analysis of stroke and systemic embolism events in the pooled rivaroxaban arms versus the VKA arm revealed no Table 5 ).
Adverse Events
No adverse events related to the intake of vitamin K2 thrice weekly after dialysis were reported. Thirty-six lifethreatening or major bleeding episodes occurred in the 132 patients, corresponding with a rate of 22.0/100 personyears. Given multiplicity of bleeding episodes within patients, which may be more related to underlying patient characteristics (e.g., angiodysplasia of the bowel) than to the type of anticoagulant, bleeding rates were analyzed both as times to first occurrence of bleeding episode and as total number of bleeding episodes. No statistically significant differences in the bleeding outcomes were found, except for the total number of combined life-threatening and major bleeding episodes being lower in both rivaroxaban arms as compared with the VKA arm ( Table 7 ). An exploratory analysis of the bleeding rates in the pooled rivaroxaban arms versus the VKA arm revealed significantly fewer major bleedings as well as combined life-threatening and major bleedings in the pooled rivaroxaban arms than in the VKA arm (Supplemental Table 6 ).
DISCUSSION
This multicenter randomized, controlled trial is the first to report the effects of vitamin K status on the progression of VC in patients on chronic hemodialysis. We did not find a difference in the progression of VC over the course of 18 months among patients treated with VKA, patients in whom the VKAwas replaced by rivaroxaban, and patients treated with rivaroxaban that additionally received high-dose vitamin K2 supplements, despite significant differences in dp-ucMGP levels, considered to be the most accurate marker of vascular vitamin K status. The conviction that correction of functional vitamin K deficiency may retard the development of VC has led to the initiation of several randomized, controlled trials of vitamin K supplements in prevalent or incident patients in hemodialysis, 11 including this study. However, this conviction rests heavily on the assumption that vitamin K deficiency can be corrected in patients on hemodialysis. Unfortunately, the results of our study reveal that withdrawal of VKAs and longterm vitamin K2 administration at pharmacologic doses does not normalize systemic dp-ucMGP levels. Initiation or continuation of VKAs led to a steady rise in dp-ucMGP concentrations. In the rivaroxaban group, dp-ucMGP decreased as a consequence of the wash-out of the VKA, but rivaroxaban had no intrinsic effect on dp-ucMGP levels, as revealed in the subgroup of patients that were VKA-naïve. Although an additional drop in dp-ucMGP was observed with vitamin K2 supplements, the median levels remained between 800 and 900 pmol/L, which is still about two-fold the value observed in healthy volunteers of the same age group that do not receive supplements. 28, 29 The question of why dp-ucMGP cannot be normalized in patients on hemodialysis is intriguing. Inactive uncarboxylated MGP is converted to active carboxylated MGP by the g-carboxylase enzyme that operates in the endoplasmic reticulum of vascular smooth muscle cells and requires vitamin K as an essential cofactor. High levels of the inactive dp-ucMGP can be taken as a prima facie confirmation of vitamin K deficiency. Multiple issues contribute to vitamin K deficiency in patients on dialysis. 11 However, long-term high-dose supplementation can be expected to overrule most of these, including the effects of deficient dietary intake, potential exhaustion of stores by high demands from the procalcific uremic environment, and abnormalities of the gut microbiome. In addition, there was no demonstrable interference by phosphate binder intake in our study. Compliance with the supplements was ascertained by administration after each dialysis session under supervision of a dialysis nurse. Finally, vitamin K removal by dialysis can be expected to be negligible due to its lipophilic nature. An alternative potential explanation for the failure to normalize dp-ucMGP is that the g-carboxylase enzyme itself is defective in uremia, even when there is an abundant supply of its cofactor vitamin K. Indeed, in experimental uremia the activity of the g-carboxylase was impaired whereas gene expression was normal. 30 Finally, MGP is produced and secreted by vascular smooth muscle cells that are known to transdifferentiate into osteoblast-like cells during the course of VC. It is tempting to speculate that the transdifferentiation process adversely affects the synthesis of active MGP.
In patients on hemodialysis, the process of VC is governed by a mosaic of factors, including disruption of calcium and phosphate metabolism and imbalance between calcification promotors and inhibitors. 31 Vitamin K deficiency thus represents only one of many pathways by which VC is accelerated. So far, single therapeutic interventions aiming at VC progression, including more frequent and extended hemodialysis, cinacalcet, phosphate binders, and cholecalciferol, have had limited success in the dialysis population. 31 Recently, magnesium oxide supplementation was found to retard the progression of calcification in the coronary arteries but not in the thoracic aorta of predialysis patients with CKD. 17 Perhaps treatment should be directed at multiple targets simultaneously; although a number of biologic processes such as oxidative stress and chronic inflammation currently remain beyond our therapeutic reach. As a final point, once VCs are advanced past a certain stage, they may no longer be susceptible to reversal and opportunities to intervene may have been missed.
Our study is the first randomized trial to report on the longterm use of DOACs to reduce thromboembolic risk in patients on hemodialysis. The overall stroke risk in our study was 4.89/ 100 person-years, taking into account that patients had a median CHA 2 DS 2 -VASc score of 5 and a 30% history of stroke. For comparison, stroke risk was 7.8/100 person-years in a Taiwanese hemodialysis population with a CHA 2 DS 2 -VASc score of 5 that did not receive oral anticoagulation. 32 A meta-analysis of 13 studies reported a stroke rate of 5.2/100 person-years in patients on hemodialysis with AF, but details on anticoagulation coverage and CHA 2 DS 2 -VASc scores were not available. 33 The incidence of ischemic or hemorrhagic stroke did not differ significantly between the rivaroxaban and VKA groups. However, it is worth noting that hemorrhagic strokes only occurred in the VKA group. In our study, the incidence of life-threatening or major bleeding was 22/100 person-years, with patients having a median HAS-BLED score of 5 and a 28% history of gastrointestinal bleeding. In the Dialysis Outcomes and Practice Patterns Study, major bleeding rates were 7.8/100 person-years in patients on oral anticoagulation and 20/100 person-years in patients with a history of gastrointestinal bleeding. 34 The results of our study reveal that severe bleeding complications may occur less frequently with rivaroxaban than with VKA.
Our study was not designed or powered to address the comparative benefits of DOACs versus VKAs with respect to stroke prevention and bleeding complications. However, because our data on stroke and bleeding are the first to be generated in a randomized, controlled trial setting, they may serve as a pilot to inform the design of larger, definitive trials to determine the optimal anticoagulation strategy in patients on hemodialysis with AF. Pending further evidence, our results suggest that rivaroxaban 10 mg once daily can be used safely and effectively in patients on hemodialysis.
The main limitation of our study is the relatively small sample size. Because it is the first clinical study to address the effects of VKAs and vitamin K supplements on the progression of VC in patients on dialysis, projections of effect size were on the basis of preliminary evidence and in hindsight appeared to have been too optimistic. Also, between-patient variability in baseline calcification scores and progression of VC was larger than anticipated. Therefore, our study has limited ability to exclude a type 2 error. Another limitation is that the population consisted mainly of prevalent patients receiving dialysis, with a high burden of cardiovascular disease as revealed by the elevated baseline calcification score and PWV, of whom the majority was taking a VKA at inclusion. As such, vascular damage may have progressed beyond a point of no return and any intervention at this stage may prove to be futile. Conversely, our study population consists of an unselected real-life cohort of patients on dialysis from three large European dialysis units. Our results therefore have direct implications for clinical practice. In conclusion, we did not find an effect of vitamin K status on VC progression in patients receiving chronic hemodialysis with AF. The results of our study highlight the complexityof the VC process, which apparently cannot be redeemed by a single intervention. Further research should be directed at optimizing vitamin K status, combining multiple interventions, and identifying a window of therapeutic opportunity perhaps long before stigmata of VC become detectable with standard techniques. 
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